Advertisement

Heart Failure Reviews

, 13:379 | Cite as

Heart failure and anemia: mechanisms and pathophysiology

  • Inder S. Anand
Article

Abstract

Anemia is a common comorbidity in patients with heart failure and affects up to 50% of patients, depending on the definition of anemia used and on the population studied. Presence of anemia and lower hemoglobin (Hgb) concentrations are powerful independent predictors of adverse outcomes in heart failure. Even small reductions in Hgb are associated with worse outcomes. Correction of anemia may be useful in improving heart failure outcomes. However, the causes of anemia in heart failure are not entirely clear. Specific causes of anemia such as hematinic abnormalities are seen only in a minority of subjects. Renal dysfunction and neurohormonal and proinflammatory cytokine activation appear to contribute to anemia of chronic disease in the majority of the patients, resulting in inappropriate erythropoietin production and defective iron utilization. Under normal conditions, reduced tissue oxygenation due to chronic anemia results in non-hemodynamic and hemodynamic compensatory responses to enhance oxygen carrying capacity. Erythropoiesis is the predominant non-hemodynamic response to hypoxia, but because erythropoiesis is defective in heart failure, hemodynamic mechanisms predominate. Hemodynamic responses are complex and involve a vasodilation-mediated high-output state with neurohormonal activation. The high-output state initially helps to increase oxygen transport. However, the hemodynamic and neurohormonal alterations could potentially have deleterious long-term consequences and could contribute to anemia’s role as an independent risk factor for adverse outcomes.

Keywords

Anemia Heart failure Erythropoietin High output heart failure Chronic kidney disease 

References

  1. 1.
    Disease Statistics (2005) NHLBI FY 2005 Fact Book: 37–56Google Scholar
  2. 2.
    Rosamond W, Flegal K, Friday G et al (2007) Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5):e69–e171PubMedCrossRefGoogle Scholar
  3. 3.
    Komajda M (2004) Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J Card Fail 10(1 Suppl):S1–S4PubMedCrossRefGoogle Scholar
  4. 4.
    Kosiborod M, Smith GL, Radford MJ et al (2003) The prognostic importance of anemia in patients with heart failure. Am J Med 114(2):112–119PubMedCrossRefGoogle Scholar
  5. 5.
    Mozaffarian D, Nye R, Levy WC (2003) Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE) J Am Coll Cardiol 41(11):1933–1939PubMedCrossRefGoogle Scholar
  6. 6.
    Tang YD, Katz SD (2006) Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113(20):2454–2461PubMedCrossRefGoogle Scholar
  7. 7.
    O’Meara E, Clayton T, McEntegart MB et al (2006) Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 113(7):986–994PubMedCrossRefGoogle Scholar
  8. 8.
    Horwich TB, Fonarow GC, Hamilton MA et al (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39(11):1780–1786PubMedCrossRefGoogle Scholar
  9. 9.
    Al-Ahmad A, Rand WM, Manjunath G et al (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38(4):955–962PubMedCrossRefGoogle Scholar
  10. 10.
    Anand I, McMurray JJ, Whitmore J et al (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110(2):149–154PubMedCrossRefGoogle Scholar
  11. 11.
    Anand IS, Kuskowski MA, Rector TS et al (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112(8):1121–1127PubMedCrossRefGoogle Scholar
  12. 12.
    Mancini DM, Katz SD, Lang CC et al (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107(2):294–299PubMedCrossRefGoogle Scholar
  13. 13.
    Silverberg DS, Wexler D, Blum M et al (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35(7):1737–1744PubMedCrossRefGoogle Scholar
  14. 14.
    Silverberg DS, Wexler D, Sheps D et al (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37(7):1775–1780PubMedCrossRefGoogle Scholar
  15. 15.
    Opasich C, Cazzola M, Scelsi L et al (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26(21):2232–2237PubMedCrossRefGoogle Scholar
  16. 16.
    Anand IS, Rector T, Deswal A et al (2006) Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J 27(Suppl 1):485Google Scholar
  17. 17.
    Maggioni AP, Opasich C, Anand I et al (2005) Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 11(2):91–98PubMedCrossRefGoogle Scholar
  18. 18.
    Philipp S, Ollmann H, Schink T et al (2005) The impact of anaemia and kidney function in congestive heart failure and preserved systolic function. Nephrol Dial Transplant 20(5):915–919PubMedCrossRefGoogle Scholar
  19. 19.
    Witte KK, Desilva R, Chattopadhyay S et al (2004) Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 147(5):924–930PubMedCrossRefGoogle Scholar
  20. 20.
    Cromie N, Lee C, Struthers AD (2002) Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart 87(4):377–378PubMedCrossRefGoogle Scholar
  21. 21.
    Westenbrink BD, Visser FW, Voors AA et al (2007) Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well Eur Heart J 28(2):166–171PubMedCrossRefGoogle Scholar
  22. 22.
    Sandek A, Bauditz J, Swidsinski A et al (2007) Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50(16):1561–1569PubMedCrossRefGoogle Scholar
  23. 23.
    Anker SD, Chua TP, Ponikowski P et al (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96(2):526–534PubMedGoogle Scholar
  24. 24.
    Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107(2):223–225PubMedCrossRefGoogle Scholar
  25. 25.
    de Silva R, Rigby AS, Witte KK, et al (2006) Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 98(3):391–398Google Scholar
  26. 26.
    Nanas JN, Matsouka C, Karageorgopoulos D et al (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48(12):2485–2489PubMedCrossRefGoogle Scholar
  27. 27.
    Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352(10):1011–1023PubMedCrossRefGoogle Scholar
  28. 28.
    Eckardt KU, Koury ST, Tan CC et al (1993) Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia. Kidney Int 43(4):815–823PubMedCrossRefGoogle Scholar
  29. 29.
    Bauer C, Kurtz A (1989) Oxygen sensing in the kidney and its relation to erythropoietin production. Annu Rev Physiol 51:845–856PubMedCrossRefGoogle Scholar
  30. 30.
    Bachmann S, Le Hir M, Eckardt KU (1993) Co-localization of erythropoietin mRNA and ecto-5’-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41(3):335–341PubMedGoogle Scholar
  31. 31.
    Mole DR, Ratcliffe PJ (2007) Cellular oxygen sensing in health and disease. Pediatr Nephrol, published online, October 23.Google Scholar
  32. 32.
    Nangaku M (2006) Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 17(1):17–25PubMedCrossRefGoogle Scholar
  33. 33.
    Anand IS, Ferrari R, Kalra GS et al (1989) Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80(2):299–305PubMedGoogle Scholar
  34. 34.
    McCullough PA, Lepor NE (2005) Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 6(Suppl 3):S4–S12PubMedGoogle Scholar
  35. 35.
    Anand IS (2005) Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 6(Suppl 3):S13–S21PubMedGoogle Scholar
  36. 36.
    McClellan WM, Flanders WD, Langston RD et al (2002) Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13(7):1928–1936PubMedCrossRefGoogle Scholar
  37. 37.
    Volpe M, Tritto C, Testa U et al (1994) Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 74(5):468–473PubMedCrossRefGoogle Scholar
  38. 38.
    George J, Patal S, Wexler D et al (2005) Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165(11):1304–1309PubMedCrossRefGoogle Scholar
  39. 39.
    van der Meer P, Voors AA, Lipsic E et al (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44(1):63–67PubMedCrossRefGoogle Scholar
  40. 40.
    Jensen JD, Eiskjaer H, Bagger JP et al (1993) Elevated level of erythropoietin in congestive heart failure relationship to renal perfusion and plasma renin. J Intern Med 233(2):125–130PubMedCrossRefGoogle Scholar
  41. 41.
    Pham I, Andrivet P, Sediame S et al (2001) Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. Eur J Clin Invest 31(2):103–109PubMedCrossRefGoogle Scholar
  42. 42.
    Deswal A, Petersen NJ, Feldman AM et al (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055–2059PubMedGoogle Scholar
  43. 43.
    Anand IS, Latini R, Florea VG et al (2005) C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112(10):1428–1434PubMedCrossRefGoogle Scholar
  44. 44.
    Rauchhaus M, Koloczek V, Volk H et al (2000) Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 76(2–3):125–133PubMedCrossRefGoogle Scholar
  45. 45.
    Jelkmann W (1998) Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18(8):555–559PubMedGoogle Scholar
  46. 46.
    Means RT Jr (2003) Recent developments in the anemia of chronic disease. Curr Hematol Rep 2(2):116–121PubMedGoogle Scholar
  47. 47.
    Macdougall IC, Cooper AC (2002) Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17(Suppl 11):39–43PubMedGoogle Scholar
  48. 48.
    Nemeth E, Rivera S, Gabayan V et al (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271–1276PubMedGoogle Scholar
  49. 49.
    Mrug M, Stopka T, Julian BA et al (1997) Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 100(9):2310–2314PubMedCrossRefGoogle Scholar
  50. 50.
    Fyhrquist F, Karppinen K, Honkanen T et al (1989) High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 226(4):257–260PubMedGoogle Scholar
  51. 51.
    Albitar S, Genin R, Fen-Chong M et al (1998) High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 13(5):1206–1210PubMedCrossRefGoogle Scholar
  52. 52.
    van der Meer P, Lipsic E, Westenbrink BD et al (2005) Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112(12):1743–1747PubMedCrossRefGoogle Scholar
  53. 53.
    Androne AS, Katz SD, Lund L et al (2003) Hemodilution is common in patients with advanced heart failure. Circulation 107(2):226–229PubMedCrossRefGoogle Scholar
  54. 54.
    Anand IS, Veall N, Kalra GS et al (1989) Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones. Eur Heart J 10(5):445–450PubMedGoogle Scholar
  55. 55.
    Kalra PR, Anagnostopoulos C, Bolger AP et al (2002) The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol 39(12):1901–1908PubMedCrossRefGoogle Scholar
  56. 56.
    Anand IS, Chandrashekhar Y, Ferrari R et al (1993) Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 70(4):357–362PubMedCrossRefGoogle Scholar
  57. 57.
    Varat MA, Adolph RJ, Fowler NO (1972) Cardiovascular effects of anemia. Am Heart J 83(3):415–426PubMedCrossRefGoogle Scholar
  58. 58.
    Oski FA, Marshall BE, Cohen PJ et al (1971) The role of the left-shifted or right-shifted oxygen-hemoglobin equilibrium curve Ann Intern Med 74(1):44–46PubMedGoogle Scholar
  59. 59.
    Metivier F, Marchais SJ, Guerin AP et al (2000) Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 15(Suppl 3):14–18PubMedGoogle Scholar
  60. 60.
    Brewer GJ (1974) 2,3-DPG and erythrocyte oxygen affinity. Annu Rev Med 25:29–38PubMedCrossRefGoogle Scholar
  61. 61.
    Schmidt W, Boning D, Braumann KM (1987) Red cell age effects on metabolism and oxygen affinity in humans. Respir Physiol 68(2):215–225PubMedCrossRefGoogle Scholar
  62. 62.
    Anand IS, Chandrashekhar Y, Wander GS et al (1995) Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol 25(6):1402–1407PubMedCrossRefGoogle Scholar
  63. 63.
    Ni Z, Morcos S, Vaziri ND (1997) Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. Kidney Int 52(1):195–201PubMedCrossRefGoogle Scholar
  64. 64.
    Anand IS, Ferrari R, Kalra GS et al (1991) Pathogenesis of edema in constrictive pericarditis. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones before and after pericardiectomy. Circulation 83(6):1880–1887PubMedGoogle Scholar
  65. 65.
    Datta BN, Silver MD (1975) Cardiomegaly in chronic anemia in rats and man experimental study including ultrastructural, histometric, and stereologic observations. Lab Invest 32(4):503–514PubMedGoogle Scholar
  66. 66.
    Olivetti G, Quaini F, Lagrasta C et al (1992) Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol 141(1):227–239PubMedGoogle Scholar
  67. 67.
    Rakusan K, Cicutti N, Kolar F (2001) Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts. Am J Physiol Heart Circ Physiol 280(3):H1407–H1414PubMedGoogle Scholar
  68. 68.
    Ishani A, Weinhandl E, Zhao Z et al (2005) Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45(3):391–399PubMedCrossRefGoogle Scholar
  69. 69.
    Go AS, Yang J, Ackerson LM et al (2006) Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation 113(23):2713–2723PubMedCrossRefGoogle Scholar
  70. 70.
    Berry C, Norrie J, Hogg K et al (2006) The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 151(6):1313–1321PubMedCrossRefGoogle Scholar
  71. 71.
    Felker GM, Shaw LK, Stough WG et al (2006) Anemia in patients with heart failure and preserved systolic function. Am Heart J 151(2):457–462PubMedCrossRefGoogle Scholar
  72. 72.
    Brucks S, Little WC, Chao T et al (2004) Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol 93(8):1055–1057PubMedCrossRefGoogle Scholar
  73. 73.
    Lauer MS, Evans JC, Levy D (1992) Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol 70(13):1180–1184PubMedCrossRefGoogle Scholar
  74. 74.
    Levin A (2001) Prevalence of cardiovascular damage in early renal disease. Nephrol Dial Transplant 16(Suppl 2):7–11Google Scholar
  75. 75.
    Levin A (2002) Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge Kidney Int Suppl 80:35–38PubMedCrossRefGoogle Scholar
  76. 76.
    Parfrey PS, Foley RN, Wittreich BH et al (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16(7):2180–2189PubMedCrossRefGoogle Scholar
  77. 77.
    Roger SD, McMahon LP, Clarkson A et al (2004) Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15(1):148–156PubMedCrossRefGoogle Scholar
  78. 78.
    Levin A (2007) The treatment of anemia in chronic kidney disease: understandings in 2006. Curr Opin Nephrol Hypertens 16(3):267–271PubMedCrossRefGoogle Scholar
  79. 79.
    Mall G, Huther W, Schneider J et al (1990) Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5(1):39–44PubMedGoogle Scholar
  80. 80.
    McCullough PA, Lepor NE (2005) The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med 6(1):1–10PubMedCrossRefGoogle Scholar
  81. 81.
    Collins AJ (2003) The hemoglobin link to adverse outcomes. Adv Stud Med 3(3C):S194–S197Google Scholar
  82. 82.
    Anker SD, Coats AJ (1999) Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 115(3):836–847PubMedCrossRefGoogle Scholar
  83. 83.
    Silverberg DS, Wexler D, Blum M et al (2003) The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18(1):141–146PubMedCrossRefGoogle Scholar
  84. 84.
    van Veldhuisen DJ, McMurray JJ (2007) Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 9(2):110–112PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Minnesota Medical SchoolMinneapolisUSA

Personalised recommendations